Evidence map›Paper›PMID 33669781›Full record

ArticleLife (Basel, Switzerland)2021

Mechanisms of Cisplatin in Combination with Repurposed Drugs against Human Endometrial Carcinoma Cells.

Chi-Kang Lin, Shu-Ting Liu, Zih-Syuan Wu, Yu-Chi Wang, Shih-Ming Huang

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Anticancer Activity of Nonpolar Pt(CHJournal of molecular structure · 2023
    Article
  10. Article
  11. Review
  12. Characteristics of the Cytotoxicity ofInternational journal of molecular sciences · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chi-Kang LinDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei City 114, Taiwan.
Shu-Ting LiuDepartment of Biochemistry, National Defense Medical Center, Taipei City 114, Taiwan.
Zih-Syuan WuDepartment of Biochemistry, National Defense Medical Center, Taipei City 114, Taiwan.
Yu-Chi WangDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei City 114, Taiwan.
Shih-Ming HuangDepartment of Biochemistry, National Defense Medical Center, Taipei City 114, Taiwan.ORCID 0000-0001-9305-921X
National Defense Medical Center · TWTri-Service General Hospital · TW

Funding

Ministry of National Defense-Medical Affairs Bureau, Taiwan MAB-109-084 to S-M HUANGMinistry of Science and Technology, Taiwan MOST-108-2320-B-016-003 to S-M HUANG and MOST-109-2221-E-016-002-MY3 to Y-C WANGTaoyuan Armed Force General Hospital 107-25 to S-M HUANG
6 · The paper itself

Abstract

Although endometrial carcinoma is one of the most common gynecological malignancies worldwide, its precise etiology remains unknown. Moreover, no novel adjuvant and/or targeted therapies are currently being developed to achieve greater efficacy for endometrial cancer patients who develop chemotherapeutic drug resistance. In this study, we used three human endometrial cancer cell lines, RL95-2, HEC-1-A, and KLE, to investigate the responsiveness of cisplatin alone and in combination with potential repurposed drugs. We first found that RL95-2 cells were more sensitive to cisplatin than HEC-1-A or KLE cells. The cytotoxicity of cisplatin in RL95-2 cells may reflect its ability to perturb the cell cycle, reactive oxygen species production and autophagy as well as to induce senescence and DNA damage. Similar effects, although not DNA damage, were also observed in HEC-1-A and KLE cells. In addition, downregulation of p53 and/or cyclin D1 may also impact the responsiveness of HEC-1-A and KLE cells to cisplatin. We also observed that resveratrol, trichostatin A (TSA), caffeine, or digoxin increased the apoptotic process of cisplatin toward RL95-2 cells, while amiodarone or TSA increased its apoptotic process toward HEC-1-A cells. The combination index supported the assertion that the combination of cisplatin with caffeine, amiodarone, resveratrol, metformin, digoxin, or TSA increases the cytotoxicity of cisplatin in HEC-1-A cells. These findings suggest potential strategies for enhancing the efficacy of cisplatin to overcome drug resistance in endometrial carcinoma patients.

Indexed as

cisplatincytotoxicityp53reactive oxygen speciesrepurposing drugs

Identifiers

PMID33669781
PMCPMC7922822
OpenAlexW3131048794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.